Stocktoria
Arbutus Biopharma Corp ABUS
Arbutus Biopharma Corp (ABUS) earns a Piotroski F-score of 3/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $14.1M at a -237.9% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ABUS | Arbutus Biopharma Corp | 3/9 | — | — | — |
| IRD | Opus Genetics, Inc. | 3/9 | -11.42 | — | +29.1% |
| PYXS | Pyxis Oncology, Inc. | 2/9 | -16.86 | — | -14.2% |
| CNTA | Centessa Pharmaceuticals plc | 4/9 | -1.11 | — | — |
| TNXP | Tonix Pharmaceuticals Holding Corp. | 3/9 | -0.37 | — | +29.8% |
| EVMN | Evommune, Inc. | 2/9 | 9.47 | — | — |
| NEUP | Neuphoria Therapeutics Inc. | 4/9 | -16.04 | — | — |
About Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
FAQ
Is ABUS financially healthy?
Arbutus Biopharma Corp's Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak).
Does ABUS pay a dividend?
No, Arbutus Biopharma Corp does not currently pay a dividend.
How profitable is ABUS?
In FY2025, Arbutus Biopharma Corp had a net margin of -237.9% and a return on equity of -43.7%.
What is the analyst price target for ABUS?
The average Wall-Street price target for Arbutus Biopharma Corp is $5.06, about 10.3% above the recent price, from 2 analysts (consensus: strong buy).
Is ABUS a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Arbutus Biopharma Corp: a Piotroski F-score of 3/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.